Zhuang 1994.

Methods	Randomisation: stated as randomised, method unclear. Allocation concealment: unclear of method Blinding: Outcome assessors were blind to treatment allocation. Study Design: Parallel. Study Setting: unclear. Analysis; Power calculation done. Withdrawals; none. Cancelled Cycles; none.
Participants	Number of women randomised: n=27 (12 growth hormone, 15 control). Definition of poor response: not provided Inclusion Criteria: previous sub‐optimal response to hyperstimulation cycles in IVF. Exclusion Criteria: Cause of subfertility: tubal factor or unexplained. Age: growth hormone 33.2 +/‐3.9, Placebo 32.3 +/‐3.9.
Interventions	Intervention: growth hormone 12 IU IM on alternate days. Treatment Protocol: GnRH‐a (Buserelin nasal spray) from day 21 of previous menstrual cycle to day of human chorionic gonadotropin injection (do not know dose of GnRH‐a) 2 IU hMG given on alternate days for 12 days (at same time as growth hormone). Dose of human chorionic gonadotropin: 10000 iu.
Outcomes	Live birth rate and pregnancy rate.
Notes	Some information will have been stated in the trial but was not translated. The sections that were translated were kindly done so by Teresa Gu.
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Stated as randomised
Allocation concealment?	Unclear risk	Not stated within the text
Blinding? All outcomes	Low risk	Single
Free of selective reporting?	Low risk	There is no indication the study has reported outcomes selectively
Free of other bias?	High risk	No details of adverse effects reported

BA: Buserelin Acetate 
 E2: Oestrogen 
 Only outcomes relevant to the review were stated in the table of included studies 
 GnRH‐a: Gonadotrophin releasing hormone agonist